Literature DB >> 26106647

Bisphosphonates: Clinical Applications and Adverse Events in Dentistry.

Angeliki A Polymeri, George J Kodovazenitis, Antonios D Polymeris, Mado Komboli.   

Abstract

PURPOSE: To review the mechanisms of action and clinical applications of bisphosphonate drugs, which are widely used in the management of metastatic bone cancer and systemic metabolic bone diseases, as well as the complications related to bisphosphonate treatment, emphasising the occurrence and management of bisphosphonate-related osteonecrosis of the jaws (BRONJ).
MATERIALS AND METHODS: A search of the medical and dental literature was conducted in Medline and Embase using a combination of the key words bisphosphonates, jaw, complications, osteonecrosis, osteoporosis and periodontal disease. A manual search of the references of the retrieved articles was also performed.
RESULTS: BRONJ predominantly affects cancer patients being treated with high-dose intravenous bisphosphonates and is characterised by the appearance of necrotic bone in the oral cavity either spontaneously or following an invasive surgical procedure such as dental extraction. The severity of this condition warrants a thorough medical and dental history in every patient in order to identify high risk patients.
CONCLUSION: It is important that dental practitioners be aware of the association between bisphosphonate treatment and osteonecrosis of the jaws. Clinicians should perform a thorough oral examination in cancer patients before they begin intravenous bisphosphonate treatment. Optimal oral hygiene and regular dental care can lower BRONJ risk. Further clinical research is necessary to unveil the full therapeutic potential of bisphosphonates, their mechanisms of action and the factors that induce unwanted side-effects.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26106647     DOI: 10.3290/j.ohpd.a34370

Source DB:  PubMed          Journal:  Oral Health Prev Dent        ISSN: 1602-1622            Impact factor:   1.256


  7 in total

1.  Radiographic evidence of treatment with bisphosphonates.

Authors:  M L T Thayer
Journal:  Br Dent J       Date:  2017-04-07       Impact factor: 1.626

2.  Panoramic radiographic features that predict the development of bisphosphonate-related osteonecrosis of the jaw.

Authors:  Ryota Kubo; Yoshiko Ariji; Tohru Taniguchi; Michihito Nozawa; Akitoshi Katsumata; Eiichiro Ariji
Journal:  Oral Radiol       Date:  2017-06-12       Impact factor: 1.852

Review 3.  Effect of adjuvant bisphosphonates on treatment of periodontitis: Systematic review with meta-analyses.

Authors:  Francisco Wilker Mustafa Gomes Muniz; Bernardo Franco da Silva; Conrado Richel Goulart; Taciane Menezes da Silveira; Thiago Marchi Martins
Journal:  J Oral Biol Craniofac Res       Date:  2021-01-21

4.  Nanoparticle-directed and ionically forced polyphosphate coacervation: a versatile and reversible core-shell system for drug delivery.

Authors:  Werner E G Müller; Emad Tolba; Shunfeng Wang; Meik Neufurth; Ingo Lieberwirth; Maximilian Ackermann; Heinz C Schröder; Xiaohong Wang
Journal:  Sci Rep       Date:  2020-10-13       Impact factor: 4.379

Review 5.  Dental Implants in People with Osteogenesis Imperfecta: A Systematic Review.

Authors:  Ole Oelerich; Johannes Kleinheinz; Lauren Bohner; Vera Wiesmüller; Marcel Hanisch
Journal:  Int J Environ Res Public Health       Date:  2022-01-29       Impact factor: 3.390

6.  Alendronate modified mPEG-PLGA nano-micelle drug delivery system loaded with astragaloside has anti-osteoporotic effect in rats.

Authors:  Yanhai Xi; Weiheng Wang; Liang Ma; Ning Xu; Changgui Shi; Guohua Xu; Hailong He; Wenming Pan
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

Review 7.  Systemic administration of strontium ranelate to enhance the osseointegration of implants: systematic review of animal studies.

Authors:  Cassio Rocha Scardueli; Carolina Bizelli-Silveira; Rosemary Adriana C Marcantonio; Elcio Marcantonio; Andreas Stavropoulos; Rubens Spin-Neto
Journal:  Int J Implant Dent       Date:  2018-07-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.